Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.

"Declarations Conflict of InterestJ.J.P.K, A.H., M.D., and M.H.D. are employees of NewAmsterdam Pharma and they also report that they receive stock or stock options. J.J.P.K is the Chief Scientific Officer of NewAmsterdam Pharma. A.H. is the Executive Director, R&D, NewAmsterdam Pharma. M.D. is the Chief Development Officer of NewAmsterdam Pharma. M.H.D. is the Chief Executive Officer of NewAmsterdam Pharma. M.R.D., as an employee of Midwest Biomedical Research, is a consultant for NewAmsterdam Pharma. In addition, M.R.D., as an employee of Midwest Biomedical Research, reports the following companies contracted consulting and/or research with their institution and it received the consulting fees and grant funding from Acasti Pharma, Beren Therapeutics, Eli Lilly and Company, Indiana University and Foundation, Matinas BioPharma, NewAmsterdam Pharma, and 89Bio. Human and Animal Rights and Informed ConsentAll reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki Declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines). Conflict of Interest J.J.P.K, A.H., M.D., and M.H.D. are employees of NewAmsterdam Pharma and they also report that they receive stock or stock options. J.J.P.K is the Chief Scientific Officer of NewAmsterdam Pharma. A.H. is the Executive Director, R&D, NewAmsterdam Pharma. M.D. is the Chief Development Officer of NewAmsterdam Pharma. M.H.D. is the Chief Executive Officer of NewAmsterdam Pharma. M.R.D., as an employee of Midwest Biomedical Research, is a consultant for NewAmsterdam Pharma. In addition, M.R.D., as an employee of Midwest Biomedical Research, reports the following companies contracted consulting and/or research with their institution and it received the consulting fees and grant funding from Acasti Pharma, Beren Therapeutics, Eli Lilly and Company, Indiana University and Foundation, Matinas BioPharma, NewAmsterdam Pharma, and 89Bio."

"Funding This manuscript was funded by NewAmsterdam Pharma, Naarden, Netherlands."